CN103479646A - Application of Kadcoccitones A to in preparation of anti-helicobacter pylori medicament - Google Patents
Application of Kadcoccitones A to in preparation of anti-helicobacter pylori medicament Download PDFInfo
- Publication number
- CN103479646A CN103479646A CN201310479160.4A CN201310479160A CN103479646A CN 103479646 A CN103479646 A CN 103479646A CN 201310479160 A CN201310479160 A CN 201310479160A CN 103479646 A CN103479646 A CN 103479646A
- Authority
- CN
- China
- Prior art keywords
- kadcoccitones
- helicobacter pylori
- preparation
- application
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of Kadcoccitones A to in preparation of an anti-helicobacter pylori medicament. The Kadcoccitones A can be applied to treatment of diseases such as acute and chronic gastritis, gastroduodenal ulcer and the like as well as preparation of medicaments for treating acute and chronic gastritis and gastroduodenal ulcer. The Kadcoccitones A belongs to a brand new matrix type, and has high inhibitory activity on helicobacter pylori and the characteristic of outstanding substantiality; meanwhile, the Kadcoccitones A is a significant progress in prevention and treatment of helicobacter pylori infection.
Description
Technical field
The present invention relates to the new purposes of compound K adcoccitones A, relate in particular to the application of Kadcoccitones A in preparing Anti-helicobacter pylori drugs.
Background technology
Helicobacter pylori (Helicobacter pylori, Hp) is a kind of Gram-negative spiral bacteria.Studies show that, helicobacter pylori is the main pathogenesis of acute and chronic gastritis and Stomach duodenum ulcer, and may be relevant with the morbidity of gastric cancer stomach function regulating mucosa-associated lymphoid tissue (MALT) malignant lymphoma.Recently, World Health Organization (WHO) is classified as I class carcinogen by Hp, and it plays a leading role in the gastric cancer development.The scheme that at present popular treatment Hp infects is to take the triple therapy that proton pump inhibitor (PPI) adds two kinds of antibiotic (clarithromycin, amoxicillin, tetracycline, metronidazole etc. select two kinds) simultaneously.The main factor that affects triple therapy is considered to the drug resistance of Hp to antibacterial; Another serious problems are that proton pump inhibitor can bring out dyspepsia, and a large amount of antibacterial cause the serious destruction of flora in digestive tract.Therefore, find the active kind new medicine thing of efficient, safe anti-Hp and become an important and urgent task.
The compound K adcoccitones A the present invention relates to is one and within 2012, delivers (Cheng-Qin Liang, et al., Kadcoccitones A and B, Two New6/6/5/5-Fused Tetracyclic Triterpenoids from Kadsura coccinea.Organic Letters, 2012, 14 (24): 6362 – 6365.) noval chemical compound, this compound has brand-new framework types, current purposes only relates to inhibiting HIV, invalid to kinds of tumors, (Cheng-Qin Liang, et al., Kadcoccitones A and B, Two New6/6/5/5-Fused Tetracyclic Triterpenoids from Kadsura coccinea.Organic Letters, 2012, 14 (24): 6362 – 6365.), it is open first that the purposes of Kadcoccitones A in preparing Anti-helicobacter pylori drugs the present invention relates to belongs to.
Summary of the invention
The object of the invention is to, according in existing Kadcoccitones A research, not finding that it has the present situation of the report of anti-helicobactor pylori activity, provides the application of Kadcoccitones A in preparing Anti-helicobacter pylori drugs.
Described compound K adcoccitones A, structure is as shown in formula I:
The experiment in vitro of Kadcoccitones A shows, Kadcoccitones A has very strong anti Helicobacter pylori activity, and paper disk method shows that its antibacterial circle diameter is 17mm (ATCC43504).Show that with agar dilution it can suppress the growth of 5 random clinical strains (Hp001, Hp003, Hp004, Hp018 and Hp036) and 1 reference culture (ATCC43504) fully, minimal inhibitory concentration (MIC) is 0.32 μ g/ml.Make positive control with ampicillin, its Cmin (MIC) that 6 strain test bacterium are suppressed fully is 3.5 μ g/ml.
This result of study shows, the energy force rate ampicillin of the inhibition helicobacter pylori activity of Kadcoccitones A is strong, explanation for the diseases such as the closely-related acute and chronic gastritis of helicobacter pylori, duodenal ulcer, Kadcoccitones A is the compound of a great exploitation potential for its.It can be directly used in the treatment of corresponding disease and the preparation of related drugs.
The purposes of the Kadcoccitones A the present invention relates in preparation treatment Anti-helicobacter pylori drugs belongs to open first, because framework types belongs to brand-new framework types, and it suppresses active strong for helicobacter pylori, possess outstanding substantive distinguishing features, the control for helicobacter pylori infections simultaneously obviously has significant progress.
The specific embodiment
The preparation method of compound K adcoccitones A involved in the present invention is referring to document (Cheng-Qin Liang, et al., Kadcoccitones A and B, Two New6/6/5/5-Fused Tetracyclic Triterpenoids from Kadsura coccinea.Organic Letters, 2012,14 (24): 6362 – 6365.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound K adcoccitones A tablet involved in the present invention:
Get 5 and digest compound Kadcoccitones A, add dextrin 195 grams, mix, conventional tabletting is made 1000.
Embodiment 2: the preparation of compound K adcoccitones A capsule involved in the present invention:
Get 5 and digest compound Kadcoccitones A, add starch 195 grams, mix, encapsulatedly make 1000.
Further illustrate its pharmaceutically active below by pharmacodynamic experiment.
The pharmacological evaluation of experimental example 1:Kadcoccitones A
1) strains tested
Helicobacter pylori reference culture ATCC43504 is purchased from U.S.'s strain and preserves center (American Type Culture Collection, ATCC).15 strain Hp clinical strains are picked up from Jiangsu Prov. People's Hospital Gastroenterology dept., clinical laboratory of Jiangsu TCM Hospital and Nanjing Children's Hospital Dndoscope Laboratory and are accepted gastroscopic patient; In continuous gastroscopy to the patient of peptic ulcer, duodenal bulbar inflammation or gastritis verrucosa, first through the RUT experiment, be defined as the Hp positive, get again antral gastric mucosa 1-2 piece, after chopping, be inoculated in the Columbia selectivity agar culture medium containing 8% horse serum, trimethoprim 1.25g/L, Polymyxin B2 500U/L, vancomycin 10mg/L, in 37 ℃, under micro-oxygen environment, (5%O2,10%CO2 and 85%N2) cultivates 72 hours.Collect antibacterial, through the smear Gram’s staining, after oxidase, catalase and urease are accredited as the positive, the pure culture of going down to posterity, obtained strains is as experimental strain.
2) strain culturing
We adopt micro-aerobic bag (purchased from Shanghai Medical Univ) to carry out the strain culturing of HP, and it can produce the needed micro-aerobic environment of Hp by chemical reaction.
3) biological activity determination
Adopt paper disk method to measure the inhibitory action of compound to helicobacter pylori, measure the minimum inhibitory concentration of test sample with agar dilution.
I. paper disk method experiment
(A) prepare culture medium by the Columbia culture medium for preparing after high pressure steam sterilization, be cooled to 50-60 ℃, add 8% horse serum or Sheep Blood, mix in the culture dish that is poured into sterilizing, every ware 7-10ml, culture medium thickness is 1.5mm (sterile working).
(B) switching experimental bacteria (be coated with bacterium) with microscale sampler get diluted 10
8cFU/ml (1OD660=10
8cFU/ml) the bacteria suspension 0.1ml of Hp spreads upon suitable culture dish surface equably.Be inverted in 37 ℃ of drying bakers and take out after 15min, purpose makes the agar surface drying, standby.
(C) pasting the sample scraps of paper gets 6 μ l testing samples (mass concentration 2mg/ml) with microscale sampler and injects on the round filter paper of sterilizing.With the aseptic nipper tweezer containing the scraps of paper of sample and the blank scraps of paper of contrast, by sterile working respectively the scraps of paper be close to containing the bacterio-agar surface, paste at a certain distance a piece of paper sheet.Every kind of bacterium is cooked 3 wares, and acquired results is asked its meansigma methods.
(D) cultivate each plate is placed in to micro-aerobic bag, sealing, open gas generator, then be placed in 37 ℃ of incubators and cultivate 72h.
(E) after surveying antibacterial circle diameter taking-up flat board, measure respectively each scraps of paper size of antibacterial circle diameter on every side.With reference to the result of matched group, can draw the result of testing sample sensitive experiment.Triplicate.
II. agar dilution is measured MIC
(A) at first the preparation of medicine flat board becomes dimethyl sulfoxide for compound (DMSO) solution preparation of test the mother solution of 0.5mg/ml, then, with the sterilized water dilution, finally is made into 10.0,8.0,6.0,4.5,4.0,3.5,3.0,2.5,2.0,1.5,1.0,0.5, with the concentration series of 0.25 μ g/ml, the concentration of DMSO in medium is less than 1%.The test compounds solution that 1ml is prepared separately adds 1ml in the 9ml Colombia culture medium of 50 ℃ and is incubated in the horse serum of 50 ℃ and fully mixes with being incubated, and casts in culture dish cooling.
(B) switching experimental bacteria (be coated with bacterium) with microscale sampler draw diluted 1 * 10
8the bacteria suspension 0.1ml of CFU/ml Hp spreads upon the culture dish surface equably, is inverted in 37 ℃ of drying bakers and takes out after 15min, and purpose makes the agar surface drying, standby.
(C) determine that MIC (contains culture dish to be measured: 85%N2,10%CO at micro-aerobic bag
2and 5%O
2) in, be incubated 37 ℃ and cultivate 72 hours, observe the Hp growing state, with blank group contrast, take and there is no the sample of bacteria growing least concentration fully as the minimum inhibitory concentration value.Positive control is ampicillin.
3, the pharmacological results of Kadcoccitones A
Experiment in vitro shows, Kadcoccitones A has very strong anti Helicobacter pylori activity, and paper disk method shows that its antibacterial circle diameter is 17mm (ATCC43504).Show that with agar dilution it can suppress the growth of 5 random clinical strains (Hp001, Hp003, Hp004, Hp018 and Hp036) and 1 reference culture (ATCC43504) fully, minimal inhibitory concentration (MIC) is 0.32 μ g/ml.Make positive control with ampicillin, its Cmin (MIC) that 6 strain test bacterium are suppressed fully is 3.5 μ g/ml.
Conclusion: it is strong that Kadcoccitones A suppresses the energy force rate ampicillin of helicobacter pylori activity, explanation for the diseases such as the closely-related acute and chronic gastritis of helicobacter pylori, duodenal ulcer, Kadcoccitones A is the compound of a great exploitation potential for its.It can be directly used in the treatment of corresponding disease and the preparation of related drugs.
Claims (1)
1.Kadcoccitones the application of A in preparing Anti-helicobacter pylori drugs, described compound K adcoccitones A structure is as shown in formula I:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310479160.4A CN103479646A (en) | 2013-10-14 | 2013-10-14 | Application of Kadcoccitones A to in preparation of anti-helicobacter pylori medicament |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310479160.4A CN103479646A (en) | 2013-10-14 | 2013-10-14 | Application of Kadcoccitones A to in preparation of anti-helicobacter pylori medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103479646A true CN103479646A (en) | 2014-01-01 |
Family
ID=49820468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310479160.4A Withdrawn CN103479646A (en) | 2013-10-14 | 2013-10-14 | Application of Kadcoccitones A to in preparation of anti-helicobacter pylori medicament |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103479646A (en) |
-
2013
- 2013-10-14 CN CN201310479160.4A patent/CN103479646A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111419829B (en) | Application of honokiol in inhibiting streptococcus suis or biofilm thereof | |
| CN102988355A (en) | Application of Aphanamixoid A for preparing helicobacter pylori resistant medicine | |
| CN102861067B (en) | Application of Houttuynoid E in preparing anti-helicobacter pylori (Hp) medicine | |
| CN103550204A (en) | Application of Neonectrolide A in preparation of anti-helicobacter pylori medicaments | |
| CN103446127B (en) | Lycojaponicumin A is preparing the application in Anti-helicobacter pylori drugs | |
| CN103463023B (en) | Application of Lycojaponicumin B in helicobacter pylori resistant medicine | |
| CN103381165B (en) | Chukrasone A is preparing the application in Anti-helicobacter pylori drugs | |
| CN103356600B (en) | Chukrasone B is preparing the application in Anti-helicobacter pylori drugs | |
| CN103446085B (en) | Incarviatone A is preparing the application in Anti-helicobacter pylori drugs | |
| CN102872154B (en) | Application of Houttuynoid B in helicobacter pylori resistant medicament | |
| CN102872132B (en) | Application of Houttuynoid D in anti-helicobacter pylori drug | |
| CN102861055B (en) | Application of Houttuynoid A in helicobacter pylori resisting medicine | |
| CN102872131B (en) | Application of Houttuynoid C in preparing anti-helicobacter pylori drug | |
| CN103690527B (en) | Aphanamgrandiol A is preparing the application in Anti-helicobacter pylori drugs | |
| CN103479646A (en) | Application of Kadcoccitones A to in preparation of anti-helicobacter pylori medicament | |
| CN102872028B (en) | Application of Gypensapogenin A in medicaments against helicobacter pylori | |
| CN103356608A (en) | Application of Fluevirosines A in preparing anti-helicobacter pylori medicines | |
| CN105535171A (en) | Rose tea | |
| CN105412087A (en) | Application of Parvifloranines A in preparing anti-helicobacter pylori medicine | |
| CN103462979A (en) | Application of spirooliganones B in preparation of medicine inhibiting helicobacter pylori | |
| CN105412052A (en) | Application of Micranthanone A in preparing drugs for anti-helicobacter pylori | |
| CN105250259A (en) | Application of Kanshone C to preparation of medicine for resisting helicobacter pylori | |
| CN105412072A (en) | Application of Rhodomollein XXV in preparation of anti-Hp (anti-Helicobacter pylori) drug | |
| CN105078970A (en) | Helicobacter pylori medicine and application thereof | |
| CN103446104A (en) | Applications of Sarcaboside B in medicament against helicobacter pylori |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20140101 |